FDA Grants Priority Review for Kyprolis® in Relapsed Patients

There was good news for myeloma patients this week as the FDA accepted the supplemental New Drug Application of Kyprolis (carfilzomib) for treatment by injection. The application applies to those with relapsed myeloma who have received at least one prior therapy. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.
Source: International Myeloma Foundation - Category: Hematology Source Type: news